^
    2d
    Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (clinicaltrials.gov)
    P2, N=532, Recruiting, Mayo Clinic | Trial completion date: May 2029 --> Feb 2031 | Trial primary completion date: May 2029 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • apalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    3d
    CGVV858A12101: Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors (2025-521911-38-00)
    P1/2, N=26, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • letrozole • goserelin acetate • leuprolide acetate for depot suspension
    13d
    SHARP: Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Jan 2027
    Trial completion date
    |
    Eligard (leuprolide acetate) • goserelin acetate • Firmagon (degarelix) • Xofigo (radium Ra-223 dichloride) • Viadur (leuprorelin implant)
    14d
    Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study (clinicaltrials.gov)
    P1, N=94, Not yet recruiting, Zhongda Hospital
    New P1 trial
    |
    docetaxel • Nubeqa (darolutamide) • goserelin acetate • Synribo (omacetaxine mepesuccinate)
    14d
    VA STARPORT: Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (clinicaltrials.gov)
    P2/3, N=464, Recruiting, VA Office of Research and Development | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • prednisone • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    14d
    Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY) (clinicaltrials.gov)
    P2, N=57, Completed, National Cancer Center Hospital East | Active, not recruiting --> Completed
    Trial completion
    |
    AR (Androgen receptor)
    |
    AR positive
    |
    Nubeqa (darolutamide) • goserelin acetate
    14d
    Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (clinicaltrials.gov)
    P3, N=2050, Active, not recruiting, NRG Oncology | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Nubeqa (darolutamide) • bicalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)
    19d
    A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy (clinicaltrials.gov)
    P3, N=391, Terminated, Jiangsu HengRui Medicine Co., Ltd. | N=1256 --> 391 | Recruiting --> Terminated; Due to the adjustment of the sponsor's development plan, after discussion with leading PI, sponsor has decided to terminate this study.
    Enrollment change • Trial termination
    |
    goserelin acetate • AiRuiEn (rezvilutamide)
    20d
    Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (clinicaltrials.gov)
    P2, N=39, Recruiting, Peking Union Medical College | Trial primary completion date: Jul 2026 --> Jul 2028
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    carboplatin • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Piqray (alpelisib) • Irene (pyrotinib) • albumin-bound paclitaxel • abiraterone acetate • fulvestrant • Aidixi (disitamab vedotin) • exemestane • Padcev (enfortumab vedotin-ejfv) • bicalutamide • Kaitanni (cadonilimab) • goserelin acetate • Qibeian (iparomlimab/tuvonralimab) • Yidafan (ivonescimab) • iparomlimab (QL1604) • leuprolide acetate for depot suspension • Entyvio (vedolizumab)
    28d
    Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (clinicaltrials.gov)
    P2, N=192, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    abiraterone acetate • apalutamide • triptorelin • goserelin acetate • AiRuiEn (rezvilutamide)
    29d
    OPTIMA-YOUNG: Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests (clinicaltrials.gov)
    P3, N=3380, Not yet recruiting, UNICANCER
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification • HER-2 negative • HER-2 expression
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    paclitaxel • docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • letrozole • epirubicin • anastrozole • exemestane • triptorelin • goserelin acetate • leuprolide acetate for depot suspension
    1m
    HYP-OP-RT: Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery. (clinicaltrials.gov)
    P=N/A, N=434, Not yet recruiting, CHU de Quebec-Universite Laval
    New trial • Head-to-Head
    |
    goserelin acetate